Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07252050 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Study acronym: RUX-HAPLO
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Sponsor changed: University of Colorado, Denver to Arkansas Children's Hospital Research Institute Start date: May 2026 to Jun 8, 2026 · Site contacts updated at 3 of 4 sitesv4 Show 2 more changesShow less
    • Start date: May 2026 to Jun 8, 2026
    • Site contacts updated at 3 of 4 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: Apr 10, 2026 to May 2026 Site contacts updated at 1 of 4 sitesv3 Show 1 more changeShow less
    • Site contacts updated at 1 of 4 sites
  3. Trial status: Not Yet Recruiting to Recruiting Start date: Jan 1, 2026 to Apr 10, 2026 · Site details revised at 4 of 4 sitesv2 Show 2 more changesShow less
    • Start date: Jan 1, 2026 to Apr 10, 2026
    • Site details revised at 4 of 4 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.
Trial Details
NCT Number NCT07252050
Lead Sponsor Arkansas Children's Hospital Research Institute
Collaborators: Children's Healthcare of Atlanta, Emory University, Incyte Corporation
Conditions Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov